A Phase I and IIa study is open to test the safety and impact on myeloma for a new monoclonal antibody targeting CD-38. The antibody will be given subcutaneously as a single agent.
The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have relapsed/refractory multiple myeloma. This study will assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of TAK-079 single therapy and will provide a preliminary assessment of its activity against multiple myeloma.
The study will enroll approximately 42 participants.
To learn more, find this study on SparkCures here:TAK-079 Clinical Trial